• Extensive-Stage Small Cell Lung Cancer — What Clinicians Want to Know About First-Line and Maintenance Therapy
    Dec 17 2025

    Dr Luis Paz-Ares from the Spanish National Oncology Research Center in Madrid and Dr Shields from Indiana University School of Medicine in Indianapolis discuss key datasets surrounding first-line and maintenance therapy for patients with extensive-stage small cell lung cancer and their clinical implications.

    CME information and select publications here.

    Show More Show Less
    58 mins
  • Lung Cancer — Proceedings from a Symposium Held in Partnership with the American Oncology Network
    Dec 12 2025

    Dr Justin F Gainor, Dr Corey J Langer and Dr Misty Dawn Shields summarize the treatment landscape and review relevant clinical datasets for patients with lung cancer.

    CME information and select publications here.

    Show More Show Less
    1 hr and 43 mins
  • HER2-Altered Non-Small Cell Lung Cancer — An Interview with Dr John V Heymach
    Dec 10 2025

    Dr John Heymach from The University of Texas MD Anderson Cancer Center in Houston discusses recent updates on available and novel treatment strategies for HER2-altered non-small cell lung cancer.

    CME information and select publications here.

    Show More Show Less
    1 hr and 5 mins
  • Lung Cancer — 5-Minute Journal Club Issue 4 with Dr Aaron Lisberg: Defining the Role of TROP2-Directed Antibody-Drug Conjugates
    Nov 10 2025

    Dr Aaron Lisberg from the University of California, Los Angeles, discusses recent developments with TROP2-directed antibody-drug conjugates in the management of non-small cell lung cancer.

    CME information and select publications here.

    Show More Show Less
    21 mins
  • Lung Cancer — 5-Minute Journal Club Issue 3 with Dr Aaron Lisberg: Defining the Role of TROP2-Directed Antibody-Drug Conjugates
    Oct 20 2025

    Dr Aaron Lisberg from the University of California, Los Angeles discusses recent developments with TROP2-directed antibody-drug conjugates in the management of non-small cell lung cancer.

    CME information and select publications here.

    Show More Show Less
    25 mins
  • Non-Small Cell Lung Cancer — 5-Minute Journal Club Issue 2 with Dr Jacob Sands: Defining the Role of TROP2-Directed Antibody-Drug Conjugates
    Sep 14 2025

    Dr Jacob Sands from Dana-Farber Cancer Institute in Boston, Massachusetts, discusses recent developments with TROP2-directed antibody-drug conjugates in the management of lung cancer.

    CME information and select publications here.

    Show More Show Less
    23 mins
  • Small Cell Lung Cancer — Expert Perspectives on Actual Patient Cases
    Aug 22 2025

    Dr Stephen V Liu from Georgetown University Hospital in Washington, DC and Dr Charles Rudin from Memorial Sloan Kettering Cancer Center in New York discuss the role of approved and novel investigational therapies for patients with limited-stage and extensive-stage small cell lung cancer.

    CME information and select publications here.

    Show More Show Less
    58 mins
  • Non-Small Cell Lung Cancer — 5-Minute Journal Club Issue 1 with Dr Jacob Sands: Defining the Role of TROP2-Directed Antibody-Drug Conjugates
    Aug 18 2025

    Dr Jacob Sands from Dana-Farber Cancer Institute in Boston, Massachusetts, discusses recent developments with TROP2-directed antibody-drug conjugates in the management of non-small cell lung cancer.

    CME information and select publications here.

    Show More Show Less
    18 mins